Key result
Euglycemic control with glyburide and metformin in T2D is linked to ~186% higher cold pressor-induced myocardial blood flow.
Why the study?
Does glucose-lowering treatment with glyburide and metformin improve coronary circulatory function in patients with type 2 diabetes?
Population
20 patients with type 2 diabetes and 18 weight-matched controls (total n=38)
Comparison
Glucose-lowering treatment with glyburide and… vs Baseline measurements and weight-matched controls
Design
Cohort
Follow-up
3 months
Authors
Loading...
May support glucose lowering improving coronary vasomotor function in T2D; hypothesis-generating and requires RCTs before practice change.
Does glucose-lowering treatment with glyburide and metformin improve coronary circulatory function in patients with type 2 diabetes?
Absolute Event Rate: 0.2% vs 0.07%
p-value: p=<0.001
Improving glycemic control with glyburide and metformin in type 2 diabetes significantly improves coronary vasomotor function, suggesting a direct link between plasma glucose levels and coronary vascular disease.
Schindler et al. (2006) studied Type 2 diabetes mellitus (n=38). Glyburide and metformin vs. Baseline (before treatment) was evaluated on Cold pressor testing-induced myocardial blood flow increase (ΔMBF) (p=<0.001). Euglycaemic control with glyburide and metformin for 3 months significantly improved the cold pressor testing-induced myocardial blood flow response from 0.07 to 0.20 ml/min/g in type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: